Cholestatic jaundice associated with chlorozotocin.
Clinical and pathologic studies of three cases of drug-induced cholestatic jaundice associated with the new antineoplastic agent chlorozotocin are presented. All three patients had received intermittent treatment with high doses of chlorozotocin. The recognition of this unusual form of hepatotoxicity is important in view of the many possible causes of jaundice in cancer patients.
D000230:Adenocarcinoma / Q000188:drug therapy; D000970:Antineoplastic Agents / Q000009:adverse effects*; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy; D002780:Cholestasis, Intrahepatic / Q000139:chemically induced* / Q000473:pathology; D006801:Humans; D008099:Liver / Q000187:drug effects / Q000473:pathology; D008175:Lung Neoplasms / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D013311:Streptozocin / Q000009:adverse effects / Q000031:analogs & derivatives*
D000970:Antineoplastic Agents; C007028:chlorozotocin; D013311:Streptozocin